BACKGROUND: The right ventricular (RV) response to pressure overload is a crucial determinant of outcomes in pulmonary arterial (PA) hypertension. Sotatercept improves clinical outcomes, but its ...
"This study revealed that exertional dyspnea, exertional palpitations, and decreased nailfold capillary density (≤ seven/mm) serve as useful indicator for considering exercise [right heart ...
Sotatercept improves exercise capacity and delays the time to clinical worsening in patients with World Health Organization (WHO) functional class II or III pulmonary arterial hypertension. The ...
Pulmonary hypertension (PH) is characterised by pathological elevation of pressure in the pulmonary circulation, driven by endothelial dysfunction, smooth muscle proliferation and inflammatory ...
Promising Phase 2 results from the international PHocus study point to the potential of the investigational inhaled drug mosliciguat for patients with pulmonary hypertension associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results